Despite the promise of target-based drug discovery ushered in by the genomics era, no mechanistically novel rationally designed antibiotic has reached clinically utility to address the threat of multi-drug resistant bacterial pathogens. Phenotypic screening remains the primary source for new antibacterial compounds, which mainly come from mining various chemical libraries. In this webinar, Carl Balibar (Merck Research Laboratories) will discuss screen design, target bias, and hit-prioritization strategies to identify those entities with the greatest opportunity to be developed into the next new antibiotic.

The overall goal of this series of webinars is to provide, for the non-clinical developer, an understanding of the risks of development for various kinds of antibacterial products. In this third webinar, we will discuss the development of antibacterial drug enhancer combinations and non-traditional products.

Please note, this webinar has been rescheduled from April 4th to May 21st, 2019.

The webinar will be held from 5:00 pm – 6:30 pm CEST / 11:00 pm – 12:30 pm EDT.

The presentation will be followed by a Q&A session.

Register here for this live webinar.